ADVL1314: A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas.

Project: Research project

Project Details

StatusFinished
Effective start/end date12/1/148/29/18

Funding

  • Children's Hospital of Philadelphia
  • Eisai Medical Research Inc.